Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2017 | Pioglitazone for the treatment of Alzheimer’s disease

Daniela Galimberti • 24 Jun 2017
EAN 2017
Alzheimer’s Disease Dementia Pioglitazone

Daniela Galimberti, PhD from the University of Milan, Milan, Italy discusses a study on pioglitazone for the treatment of Alzheimer’s disease at the 2017 Congress of the European Academy of Neurology (EAN) in Amsterdam, the Netherlands. The drug acts on a receptor involved in inflammatory mechanisms and the rationale is to interfere with inflammation in Alzheimer’s disease.

More from Daniela Galimberti

1:15
Risk factors for developing dementia
Daniela Galimberti • 24 Jun 2017
1:27
Genetic counseling for dementia
Daniela Galimberti • 25 Jun 2017

Related Videos

3:58
Promising FONLISA test for ultrasensitive detection of plasma NfL in Alzheimer’s disease
Madison Honey • 7 Mar 2024
4:12
Updates in Alzheimer’s treatment: the potential of NSC001
Manfred Windisch • 6 Mar 2024
4:44
Influence of genetic risk for psychiatric disorders on dementia
Jenna Najar • 6 Mar 2024
2:31
Barriers to dementia treatment: awareness, accessibility, and affordability
Paola Barbarino • 23 Mar 2024
The content of VJDementia is intended for healthcare professionals